Shared and distinct mechanisms of UBA1 inactivation across different diseases
Jason C Collins,Samuel J Magaziner,Maya English,Bakar Hassan,Xiang Chen,Nicholas Balanda,Meghan Anderson,Athena Lam,Sebastian Fernandez-Pol,Bernice Kwong,Peter L Greenberg,Benjamin Terrier,Mary E Likhite,Olivier Kosmider,Yan Wang,Nadine L Samara,Kylie J Walters,David B Beck,Achim Werner
DOI: https://doi.org/10.1038/s44318-024-00046-z
2024-02-16
The EMBO Journal
Abstract:Most cellular ubiquitin signaling is initiated by UBA1, which activates and transfers ubiquitin to tens of E2 enzymes. Clonally acquired UBA1 missense mutations cause an inflammatory-hematologic overlap disease called VEXAS (vacuoles, E1, X-linked, autoinflammatory, somatic) syndrome. Despite extensive clinical investigation into this lethal disease, little is known about the underlying molecular mechanisms. Here, by dissecting VEXAS-causing UBA1 mutations, we discovered that p.Met41 mutations alter cytoplasmic isoform expression, whereas other mutations reduce catalytic activity of nuclear and cytoplasmic isoforms by diverse mechanisms, including aberrant oxyester formation. Strikingly, non-p.Met41 mutations most prominently affect transthioesterification, revealing ubiquitin transfer to cytoplasmic E2 enzymes as a shared property of pathogenesis amongst different VEXAS syndrome genotypes. A similar E2 charging bottleneck exists in some lung cancer-associated UBA1 mutations, but not in spinal muscular atrophy-causing UBA1 mutations, which instead, render UBA1 thermolabile. Collectively, our results highlight the precision of conformational changes required for faithful ubiquitin transfer, define distinct and shared mechanisms of UBA1 inactivation in diverse diseases, and suggest that specific E1-E2 modules control different aspects of tissue differentiation and maintenance.
cell biology,biochemistry & molecular biology